Partenaires

CNRS
Logo Université de Strasbourg
Logo IREBS



Rechercher

Sur ce site

Sur le Web du CNRS


Accueil > Biotechnology and cell signalling (Jean-Luc Galzi)
(UMR 7242)
> Receptors, membrane proteins and therapeutic innovation (Scientific coordination : Isabelle Schalk) > GPCRs in cardiobiology (Canan Nebigil-Desaubry) > Publications > Publications of the team RCGPs and cardiology

Publications of the team RCGPs and cardiology

Updated : 02/12/2015

- 2015

Qureshi R, Yildirim O, Gasser A, Basmadjian C, Zhao Q, Wilmet JP, Désaubry L, Nebigil CG.
FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity
PLoS One. 2015,10, e0141826-DOI

Von Hunolstein JJ, Nebigil CG.
Can prokineticin prevent obesity and insulin resistance?
Curr Opin Endocrinol Diabetes Obes. 2015, 22, 367-73-DOI

Gasser A, Brogi S, Urayama K, Nishi T, Kurose H, Tafi A, Ribeiro N, Désaubry L, Nebigil CG.
Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1
PLoS One. 2015, 10, 4, e0121027-DOI

- 2014

Brogi S, Tafi A, Désaubry L, Nebigil CG.
Discovery of GPCR ligands for probing signal transduction pathways.
Front Pharmacol. 2014, 5, 255-DOI

Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry LG.
Cancer wars: natural products strike back
Front Chem. 2014, 2, 20 - DOI

Top of page

 

- 2013

Nguyen TL, Gasser A, Nebigil CG.
Role of Prokineticin Receptor-1 in Epicardial Progenitor Cells.
J. Dev. Biol. 2013 1, 20-31. DOI

Szatkowski C, Vallet J, Dormishian M, Messaddeq N, Valet P, Boulberdaa M, Metzger D, Chambon P, Nebigil CG.
Prokineticin receptor 1 as a novel suppressor of preadipocyte proliferation and differentiation to control obesity.
PLoS One. 2013 Dec 4;8(12):e81175 - DOI

Dormishian M, Turkeri G, Urayama K, Nguyen TL, Boulberdaa M, Messaddeq N, Renault G, Henrion D, Nebigil CG.
Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions.
J Am Heart Assoc. 2013 2(5):e000411 - DOI

Thuaud F, Ribeiro N, Nebigil CG, Désaubry L.
Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.
Chem Biol. 2013 Mar 21;20(3):316-31. DOI

Top of page

 

- 2012

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Désaubry L.
Flavaglines as potent anticancer and cytoprotective agents.
J Med Chem. 2012 Nov 26;55(22):10064-10073. - DOI

Ribeiro N., Thuaud, F., Nebigil, C.G., Désaubry, L.
Recent advances in the biology and chemistry of the flavaglines.
Bioorg Med Chem. 2012, 20(6):1857-1864. Review. - DOI

Top of page

 

- 2011

Bernard,Y., Ribeiro N., Thuaud, F., Türkeri, G., Dirr, R., Boulberdaa, M., Nebigil, C.G., Désaubry, L.
Flavaglines alleviate doxorubicin cardiotoxicity: Implication of Hsp27.
Plos One 2011, 6(10), e25981 - DOI

Boulberdaa, M., Urayama, K., Nebigil. C.G.
Prokineticin receptor 1 (PKR1) in heart and kindey functions.
Cardiovasc. Res. 2011, 92, 191-198 - DOI

Boulberdaa M., Turkeri G., Urayama K., Dormishian M., Szatkowski C., Zimmer L., Messaddeq N., Laugel V., Dollé P., Nebigil C.G.
Genetic inactivation of prokineticin receptor-1 leads to heart and kidney disorders.
Arterioscler. Thromb. Vasc. Biol 2011 31, 842-850 - DOI

Top of page

 

- 2010

Guilini C., Urayama K., Turkeri G., Dedeoglu D.B., Kurose H., Messadeq N., Nebigil C.G.
Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration.
Am J Physiol Heart Circ Physiol. 2010, 298, H844-52 - DOI

Nebigil C.G. 

Prokineticin receptors in cardiovascular function. 

In : Shaping the Heart in Development and Disease, (Alexander T. Mikhailov and Mario Torrado, eds.) 2010, 978-981

Top of page

 

- 2009

Nebigil C.G.
Prokineticin receptor signaling in cardiovascular function: Foes or Friends?
Trends in Cardiovascular Medicine 2009 19, 55-60 - DOI

Thuaud F., Bernard Y., Türkeri G., Dirr R., Aubert G., Cresteil T., Baguet A., Tomasetto C., Svitkin Y., Sonenberg N., Nebigil C.G., Désaubry L.
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of AIF.
J. Med Chem. 2009 52, 5176-87 - DOI

Urayama K., Dedeoglu D.B., Messaddeq N., Hu K., Ert G., Nebigil C.G.
Transgenic myocardial overexpression of prokineticin receptor-2 induces compensatory hypertrophy and vascular leakage.
Cardiovasc. Research 2009 81, 28-37 - DOI

Top of page

 

- 2008

Urayama K., Guilini C., Turkeri G., Takir S., Messaddeq N., Nebigil C.G.
Prokineticin receptor-1 induces neovascularization and epicardial derived progenitor cell differentiation.
Arter. Thromb. Vas. Biol. 2008 28, 841-9 - DOI

 

- 2007

Urayama K., Guilini C., Messaddeq N., Hu K., Steenman M., Kurose H., Ert G., Nebigil C.G.
The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis.
FASEB J. 2007 21, 2980-93 - DOI

Top of page

 

- 2006

Nebigil C.
Prokineticin receptor in cardiomyocyte survival and angiogenesis.
Circulation 2006 114, 158

 

- 2004

Jaffre, F., J. Callebert, A. Sarre, N. Etienne, C.G. Nebigil, J.M. Launay, L. Maroteaux, L. Monassier
Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts.
Circulation 2004 110, 969-74

Top of page

- Retour to the home page